Methods of treating or preventing inflammation and hypersensitivity with oxidative reductive potential water solution

• US 20070196357A1
• Filed: 01/22/2007
• Published: 08/23/2007
• Est. Priority Date: 01/20/2006
• Status: Abandoned Application

• Current Assignee: Sonoma Pharmaceuticals, Inc.
• Original Assignee: Oculus Innovative Sciences, Inc
• Inventors: Gutierrez, Andres, Alimi, Hojabr
• Application Number:
  US11/656,087
• Publication Number:
  US 20070196357A1
• Time in Patent Office: Days
• US Class Current: 424/114
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 33/00 Medicinal preparations containing inorganic active ingredients
• CPC Class Codes: A61K 33/20 Elemental chlorine; Inorganic compounds releasing chlorine
• CPC Class Codes: A61K 33/40 Peroxides
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61P 1/02 Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
• CPC Class Codes: A61P 1/04 for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• CPC Class Codes: A61P 11/02 Nasal agents, e.g. decongestants
• CPC Class Codes: A61P 11/06 Antiasthmatics
• CPC Class Codes: A61P 17/00 Drugs for dermatological disorders
• CPC Class Codes: A61P 19/02 for joint disorders, e.g. arthritis, arthrosis
• CPC Class Codes: A61P 21/00 Drugs for disorders of the muscular or neuromuscular system
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 31/00 Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• CPC Class Codes: A61P 31/04 Antibacterial agents
• CPC Class Codes: A61P 31/10 Antimycotics
• CPC Class Codes: A61P 31/12 Antivirals
• CPC Class Codes: A61P 31/14 for RNA viruses
• CPC Class Codes: A61P 31/16 for influenza or rhinoviruses
• CPC Class Codes: A61P 31/20 : for DNA viruses
• CPC Class Codes: A61P 37/02 : Immunomodulators
• CPC Class Codes: A61P 37/08 : Antiallergic agents antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14
• CPC Class Codes: A61P 43/00 : Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: Y02A 50/30 : Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Provided is a method for preventing or treating inflammation and associated states (e.g. infection, hypersensitivity, pain) by administering a therapeutically effective amount of an oxidative reduction potential (ORP) water solution that is stable for at least about twenty-four hours. The ORP water solution administered in accordance with the invention can be combined with one or more suitable carriers and can be administered in conjunction with one or more additional therapeutic agents.

Claims

1. A method of preventing or treating inflammation in a patient, the method comprising administering to the patient a therapeutically effective amount of an oxidative reductive potential water solution, wherein the solution is stable for at least about twenty-four hours and the solution has a pH of from about 6.4 to about 7.8.

2. The method of claim 1, wherein the oxidative reductive potential water solution is administered topically.

3. The method of claim 1, wherein the oxidative reductive potential water solution is administered parenterally.

4. The method of claim 1, wherein the oxidative reductive potential water solution is administered endoscopically.

5. The method of claim 1, wherein the oxidative reductive potential water solution is administered to a mucosal surface.

6. The method of claim 1, wherein the oxidative reductive potential water solution is administered to one or more tissues selected from the group consisting of nasal, sinus, pharyngeal, tracheal, pulmonary, esophageal, gastric, intestinal, mesothelial, peritoneal, synovial, urinary bladder, urethral, vaginal, uterine, fallopian, pancreatic, nervous, oral, cutaneous, and subcutaneous.

7. The method of claim 1, wherein the oxidative reductive potential water solution is administered as a liquid, steam, aerosol, mist or spray.

8. The method of claim 1, wherein the oxidative reductive potential water solution is administered by aerosolization, nebulization or atomization.

9. The method of claim 1, wherein the oxidative reductive potential water solution is administered in the form of droplets having a diameter in the range of from about 0.1 micron to about 100 microns.

10. The method of claim 1, wherein the inflammation is acute inflammation.

11. The method of claim 1, wherein the inflammation is chronic inflammation.

12. The method of claim 1, wherein the inflammation results from a hypersensitivity reaction.

13. The method of claim 1, wherein the inflammation is associated with cellular histamine and pro-inflammatory cytokine release.

14. The method of claim 1, wherein the inflammation is cell-mediated.

15. The method of claim 1, wherein the oxidative reductive potential water solution inhibits mast cell degranulation.

16. The method of claim 1, wherein the oxidative reductive potential water solution inhibits mast cell cytokine secretion.

17. The method of claim 1, wherein the method comprises treating one or more diseases or conditions selected from the group consisting of allergic rhinosinusitis, atopic dermatitis, food allergies, asthma, SLE, autoimmune thyroiditis, sarcoidosis, inflammatory bowel disease, rheumatoid arthritis, multiple sclerosis, and rheumatic fever.

18. The method of claim 1, wherein the inflammation is caused by an autoimmune reaction.

19. The method of claim 1, wherein the inflammation is caused by an infection.

20. The method of claim 19, wherein the infection is by one or more microorganisms selected from the group consisting of viruses, bacteria, and fungi.

21. The method of claim 1, wherein the oxidative reductive potential water solution is stable for at least about one week.

22. The method of claim 1, wherein the oxidative reductive potential water solution is stable for at least about two months.

23. The method of claim 1, wherein the oxidative reductive potential water solution is stable for at least about six months.

24. The method of claim 1, wherein the oxidative reductive potential water solution is stable for at least about one year.

25. The method of claim 1, wherein the pH of the oxidative reductive potential water solution is from about 7.4 to about 7.6.

26. The method of claim 1, wherein the oxidative reductive potential water solution comprises a mixture of cathode water and anode water.

27. The method of claim 1, wherein the oxidative reductive potential water solution comprises cathode water in an amount of from about 10% to about 50% by volume of the solution.

28. The method of claim 1, wherein the oxidative reductive potential water solution comprises cathode water in an amount of from about 20% to about 40% by volume of the solution.

29. The method of claim 1, wherein the oxidative reductive potential water solution comprises anode water in an amount of from about 50% to about 90% by volume of the solution.

30. The method of claim 1, wherein the oxidative reductive potential water solution comprises from about 10% by volume to about 50% by volume of cathode water and from about 50% by volume to about 90% by volume of anode water.

31. The method of claim 1, wherein the oxidative reductive potential water solution comprises at least one free chlorine species selected from the group consisting of hypochlorous acid, hypochlorite ions, sodium hypochlorite, chlorite ions, chloride ions, dissolved chlorine gas, and mixtures thereof and, optionally, hydrogen peroxide and/or chlorine dioxide.

32. The method of claim 1, wherein the oxidative reductive potential water solution comprises from about 15 ppm to about 35 ppm hypochlorous acid.

33. The method of claim 1, wherein the oxidative reductive potential water solution comprises from about 25 ppm to about 50 ppm sodium hypochlorite.

34. The method of claim 1, wherein the oxidative reductive potential water solution comprises from about 15 ppm to about 35 ppm hypochlorous acid, from about 25 ppm to about 50 ppm sodium hypochlorite, a pH of from about 6.2 to about 7.8, and the solution is stable for at least one week.

35. The method of claim 1, wherein the oxidative reductive potential water solution has a potential between about −

400 mV and about +1300 mV.

36. The method of claim 1, further comprising administering at least one therapeutic agent selected from the group consisting of antibiotics, anti-viral agents, and anti-inflammatory agents, and combinations thereof.